12,221 Shares in Arrowhead Pharmaceuticals, Inc. $ARWR Bought by Pale Fire Capital SE

Key Points

• Pale Fire Capital SE has acquired a new stake in Arrowhead Pharmaceuticals, purchasing 12,221 shares valued at approximately $156,000.
• Institutional investors and hedge funds collectively own 62.61% of Arrowhead Pharmaceuticals stock, with Vanguard Group increasing its stake by 8.4% in the first quarter.
• Arrowhead Pharmaceuticals missed earnings expectations for the quarter, reporting a loss of ($1.26) per share and revenue of $27.77 million, below the anticipated $29.01 million.

Pale Fire Capital SE bought a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 12,221 shares of the biotechnology company's stock, valued at approximately $156,000.

A number of other hedge funds have also recently added to or reduced their stakes in ARWR. GAMMA Investing LLC boosted its position in Arrowhead Pharmaceuticals by 297.6% in the first quarter. GAMMA Investing LLC now owns 2,175 shares of the biotechnology company's stock valued at $28,000 after buying an additional 1,628 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in Arrowhead Pharmaceuticals in the fourth quarter valued at approximately $49,000. CWM LLC boosted its position in Arrowhead Pharmaceuticals by 134.3% in the first quarter. CWM LLC now owns 4,401 shares of the biotechnology company's stock valued at $56,000 after buying an additional 2,523 shares in the last quarter. KBC Group NV boosted its position in Arrowhead Pharmaceuticals by 40.8% in the first quarter. KBC Group NV now owns 7,356 shares of the biotechnology company's stock valued at $94,000 after buying an additional 2,132 shares in the last quarter. Finally, XTX Topco Ltd acquired a new stake in Arrowhead Pharmaceuticals in the first quarter valued at approximately $133,000. Institutional investors and hedge funds own 62.61% of the company's stock.

Insiders Place Their Bets

In related news, insider James C. Hamilton sold 9,389 shares of Arrowhead Pharmaceuticals stock in a transaction on Friday, August 15th. The shares were sold at an average price of $20.00, for a total transaction of $187,780.00. Following the completion of the transaction, the insider owned 262,122 shares of the company's stock, valued at $5,242,440. This trade represents a 3.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 4.30% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. Citigroup cut their target price on shares of Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating on the stock in a research report on Tuesday, May 13th. Wall Street Zen lowered shares of Arrowhead Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Friday, July 18th. HC Wainwright reiterated a "buy" rating and set a $80.00 price target on shares of Arrowhead Pharmaceuticals in a report on Tuesday, May 20th. TD Cowen upgraded shares of Arrowhead Pharmaceuticals to a "strong-buy" rating in a report on Monday, July 28th. Finally, Chardan Capital reiterated a "buy" rating and set a $60.00 price target on shares of Arrowhead Pharmaceuticals in a report on Monday, August 11th. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, Arrowhead Pharmaceuticals presently has an average rating of "Buy" and a consensus price target of $43.14.

Arrowhead Pharmaceuticals Trading Down 2.7%

NASDAQ ARWR traded down $0.60 during mid-day trading on Friday, reaching $21.75. 813,271 shares of the stock were exchanged, compared to its average volume of 1,956,865. Arrowhead Pharmaceuticals, Inc. has a one year low of $9.57 and a one year high of $27.34. The stock has a 50 day simple moving average of $17.58 and a 200-day simple moving average of $16.00. The stock has a market cap of $3.01 billion, a P/E ratio of -16.96 and a beta of 0.94. The company has a debt-to-equity ratio of 0.39, a current ratio of 4.87 and a quick ratio of 4.87.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last announced its earnings results on Thursday, August 7th. The biotechnology company reported ($1.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.94) by ($0.32). The company had revenue of $27.77 million for the quarter, compared to analyst estimates of $29.01 million. During the same period in the previous year, the company earned ($1.38) earnings per share. On average, analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.